- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01301820
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)
Phase II Multicentric Trial Maintenance Therapy With 6 Monthly Revlimid® Cycles Alternated With 6 Monthly Vidaza® Cycles in First CR After Induction LIA Chemotherapy for Elderly Fit Patients With Poor Prognosis Acute Myeloid Leukemia.
Phase II Multicentric Trial Open Label, Multicenter, randomized to evaluate the efficacy of a Maintenance Therapy in First Complete Remission After Induction for Elderly (≥ 60) Fit Patients With Poor Prognosis Acute Myeloid Leukemia (AML).
The disease-free survival (DFS) of the patients included in this study will be compared to the ones of the two previously reported groups of patients treated with the same LIA induction therapy
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
- The primary objective of this study will be to improve the DFS with an alternate schema combining azacitidine and lenalidomide in elderly fit patients with previously untreated AML and with high risk cytogenetics or secondary AML, who achieved either a complete remission after an LIA induction therapy
- The secondary objectives will be to determine the relapse incidence, overall survival, event free survival at 1 and 2 years of follow-up, toxicities of the treatment, incidence of infectious events.
- To define a gene expression and promoter methylation signatures associated with CR and absence of relapse when patients received azacitidine and lenalidomide. Gene promoter methylation and gene expression profiling will be performed at diagnosis, at CR, and after 2 courses of azacitidine and lenalidomide in order to give insight within the mechanisms involved by the use of these 2 drugs and to identify new epigenetic prognostic markers.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Angers, Francia, 49033
- Mathilde HUNAULT BERGER
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Cytologically or histologically confirmed acute myeloid leukemia (AML) with :
- At least 60 years of age and fit for intensive chemotherapy: PS <2 (ECOG)
- Absence of significant co-morbidities
- Less than 75 years* of age
- LAM with high risk features (blasts > 20% in bone marrow)
- Poor risk cytogenetics
- Life expectancy > 1 month
- Affiliated to social security regimen
- No granulocytic sarcoma as sole site of disease
- Able and willing to provide written and signed informed consent
Exclusion Criteria:
- Total bilirubin > 2 times upper limit of normal
- AST and ALT and/or alkaline phosphatase > 4 times upper limit of normal if not in relation with AML.
- Factor V < 50% without DIC (Disseminated Intravascular Coagulation)
- NYHA class III or IV congestive heart failure (Echo < 40%, LVEF < 50%),Unstable angina pectoris, Serious cardiac arrhythmia
- Renal failure not related to AML: serum creatinin > 170 μmol/L or clearance of creatinin ≤ 50 mL/mn
- Known HIV 1- HIV 2 positivity
- Prior therapy with azacitidine or lenalidomide
- Psychiatric illness or social situations that would preclude compliance with study requirements
- Uncontrolled infection
- Urgent chemotherapy for DIC, spontaneous tumoral lyse syndrome, leucostase without cytogentic results
- Women who are pregnant or breastfeeding
- Women who are unwilling or unable to use an acceptable contraceptive method to avoid pregnancy
- Men who are unwilling or unable to use an acceptable method of birth control
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: ARM A
maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
|
azacitidine sc 75 mg/m²/d (d1- d7)
Altri nomi:
|
Altro: ARM B
maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
|
lenalidomide 10mg/d (d1- d21)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
DFS
Lasso di tempo: 18 months
|
The primary objective of this study will be to improve the DFS with an alternate schema combining azacitidine and lenalidomide in elderly fit patients with previously untreated AML and with high risk cytogenetics or secondary AML, who achieved either a complete remission after an LIA induction therapy.
|
18 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
relapse incidence OS EFS Infectious events
Lasso di tempo: until death
|
The secondary objectives will be to determine the relapse incidence, overall survival, event free survival at 1 and 2 years of follow-up, toxicities of the treatment, incidence of infectious events.
|
until death
|
gene expression and promoter methylation signatures associated with CR
|
To define a gene expression and promoter methylation signatures associated with CR and absence of relapse when patients received azacitidine and lenalidomide.
Gene promoter methylation and gene expression profiling will be performed at diagnosis, at CR, and after 2 courses of azacitidine and lenalidomide in order to give insight within the mechanisms involved by the use of these 2 drugs and to identify new epigenetic prognostic markers.
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Mathilde HUNAULT BERGER, MD PD, French Innovative Leukemia Organisation
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Leucemia
- Leucemia, mieloide
- Leucemia, mieloide, acuta
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Antimetaboliti, Antineoplastici
- Antimetaboliti
- Agenti antineoplastici
- Fattori immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Lenalidomide
- Azacitidina
Altri numeri di identificazione dello studio
- LAMSA-maintenance Rev-5Aza
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Leucemia mieloide acuta
-
Region of Southern DenmarkOdense Municipality, Denmark; Kerteminde Municipality, Denmark; Svendborg Municipality...Completato
-
Peking University Third HospitalShanghai Jiao Tong University School of MedicineAttivo, non reclutante
-
University of Southern DenmarkCompletatoCondizioni mediche acuteDanimarca
-
AstraZenecaCompletatoRiacutizzazioni acute della BPCOCina
-
Assiut UniversityCompletato
-
Central Hospital, Nancy, FranceSconosciutoCondizioni acute in terapia intensivaFrancia
-
Centre Hospitalier Universitaire de NiceCompletato
-
GlaxoSmithKlineCompletato
-
Vanderbilt UniversityTerminatoLesioni polmonari, acuteStati Uniti
-
All India Institute of Medical Sciences, RishikeshSconosciutoLesioni polmonari, acute
Prove cliniche su azacitidine
-
Ohio State University Comprehensive Cancer CenterMillennium Pharmaceuticals, Inc.; Celgene CorporationCompletatoSindromi mielodisplastiche | Leucemia | Neoplasie mielodisplastiche/mieloproliferativeStati Uniti